文献速递真实世界研究与卫生经济流行病学与生物统计

美国单一支付者医疗融资的预计成本:经济分析系统综述

Projected costs of single-payer healthcare financing in the United States: A systematic review of economic analyses.
PubMed 文献 · PLoS Med · 2020-01-15

该系统综述检索了PubMed、Google、Google Scholar及既有清单,并咨询专家小组,纳入过去30年针对美国或各州单一支付者方案的22项正式经济分析。结果显示,19项(86%)分析预测项目实施首年净节省,中位净结果为总成本节省3.46%;20项(91%)预测数年内节省。节省主要来自简化支付管理,净节省的最佳预测因素为使用量增幅及管理与药品成本节省。

要点

  • 多数经济分析预测单一支付者方案首年即净节省,中位节省为总成本的3.46%。
  • 简化支付管理是最大节省来源,中位节省8.8%。
  • 实际成本取决于方案设计与实施,研究间方法异质性大。

核心结论

  • 该系统综述发现,美国单一支付者方案在财政可行性上存在高度分析共识。
  • 实际成本将取决于方案特征与实施方式。
  • 未来研究应细化覆盖扩大对使用量影响的估计,并评估不同现有单一支付者体系下的提供者管理成本。

研究设计与样本

  • 检索PubMed、Google、Google Scholar及既有清单,并咨询专家小组。
  • 纳入过去30年22项单一支付者方案的经济分析,由双人按模板提取方法与结果数据。
  • 排除技术数据不足或假设私营保险商持续发挥实质作用的分析。
  • 将总成本变化标准化为同期医疗支出的百分比,并按成本亚型量化。

主要发现

  • 19项(86%)分析预测项目实施首年净节省,中位净结果为总成本节省3.46%。
  • 20项(91%)分析预测数年内节省,预期增长率将使所有方案实现长期净节省。
  • 最大节省来源为简化支付管理,中位8.8%。
  • 净节省的最佳预测因素为使用量增幅、管理节省与药品成本节省,R2分别为0.035、0.43、0.62。
  • 多变量分析中仅药品成本节省仍显著。

关键数值与推荐

  • 纳入分析的方案数:22项单一支付者方案的经济分析。
  • 预测首年净节省的分析:19项(86%),中位净节省为总成本的3.46%。
  • 预测数年内节省的分析:20项(91%)。
  • 简化支付管理节省中位值:8.8%。
  • 净节省预测因素R2:使用量增幅0.035、管理节省0.43、药品成本节省0.62。

临床怎么用

  • 解读单一支付者方案成本时,应关注方案设计、实施方式及建模假设的差异。
  • 评估财政影响时可重点考察使用量增幅、支付管理简化与药品成本节省三类因素。
  • 引用预测结果时需注意其为模型推算而非实际实施成本。

局限性

  • 纳入研究的方法异质性较大,无法进行正式Meta分析。
  • 实际成本将取决于方案特征与实施情况,预测值存在不确定性。
  • 部分研究因技术数据不足或假设私营保险商持续发挥实质作用而被排除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The United States is the only high-income nation without universal, government-funded or -mandated health insurance employing a unified payment system. The US multi-payer system leaves residents uninsured or underinsured, despite overall healthcare costs far above other nations. Single-payer (often referred to as Medicare for All), a proposed policy solution since 1990, is receiving renewed press attention and popular support. Our review seeks to assess the projected cost impact of a single-payer approach. METHODS AND FINDINGS: We conducted our literature search between June 1 and December 31, 2018, without start date restriction for included studies. We surveyed an expert panel and searched PubMed, Google, Google Scholar, and preexisting lists for formal economic studies of the projected costs of single-payer plans for the US or for individual states. Reviewer pairs extracted data on methods and findings using a template. We quantified changes in total costs standardized to percentage of contemporaneous healthcare spending. Additionally, we quantified cost changes by subtype, such as costs due to increased healthcare utilization and savings due to simplified payment administration, lower drug costs, and other factors. We further examined how modeling assumptions affected results. Our search yielded economic analyses of the cost of 22 single-payer plans over the past 30 years. Exclusions were due to inadequate technical data or assuming a substantial ongoing role for private insurers. We found that 19 (86%) of the analyses predicted net savings (median net result was a savings of 3.46% of total costs) in the first year of program operation and 20 (91%) predicted savings over several years; anticipated growth rates would result in long-term net savings for all plans. The largest source of savings was simplified payment administration (median 8.8%), and the best predictors of net savings were the magnitude of utilization increase, and savings on administration and drug costs (R2 of 0.035, 0.43, and 0.62, respectively). Only drug cost savings remained significant in multivariate analysis. Included studies were heterogeneous in methods, which precluded us from conducting a formal meta-analysis. CONCLUSIONS: In this systematic review, we found a high degree of analytic consensus for the fiscal feasibility of a single-payer approach in the US. Actual costs will depend on plan features and implementation. Future research should refine estimates of the effects of coverage expansion on utilization, evaluate provider administrative costs in varied existing single-payer systems, analyze implementation options, and evaluate US-based single-payer programs, as available.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Cai C, Runte J, Ostrer I, et al. Projected costs of single-payer healthcare financing in the United States: A systematic review of economic analyses. PLoS Med. 2020. PMID: 31940342. doi:10.1371/journal.pmed.1003013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。